Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems. In obesity, GLP-1 drugs such as Wegovy transformed the company into a perceived structural growth leader. The stock was priced for durable dominance. The pullback reflects emerging limits to that assumption.
The US obesity population suggests a theoretical GLP-1 market exceeding $80 billion annually by 2035. However, realised revenue depends on access. Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand. Reimbursement remains uneven. Medicare does not broadly cover obesity medications, and commercial payors impose strict prior authorisation due to budget impact. While the SELECT cardiovascular outcomes data strengthens the health economic argument, it has not yet triggered universal coverage expansion.
Competition is intensifying. Eli Lilly’s tirzepatide has demonstrated superior weight loss efficacy, influencing prescriber preference and payer formulary positioning. If long-term US penetration stabilises at 6 to 8 percent rather than 12 to 15 percent, and Novo’s market share settles closer to 35 percent, obesity revenue could plateau around $25 to $30 billion. On a 12 to 14 times earnings multiple, that supports a far more modest valuation than peak expectations implied.
Novo’s future equity value will depend on sustained reimbursement expansion, manufacturing execution, and lifecycle innovation through 2035.
Have other thoughts on Novo Nordisk?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user ctmlin910 holds no position in CPSE:NOVO B. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
